BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang Y, Xu Y, Su A, Yang D, Zhang X. Effects of Deferoxamine on Leukemia In Vitro and Its Related Mechanism. Med Sci Monit 2018;24:6735-41. [PMID: 30246777 DOI: 10.12659/MSM.910325] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang F, Wu Z, Dai D, Zhang L, Zhang X, Zhang X, Xu Y. The iron chelator deferoxamine decreases myeloma cell survival. J Int Med Res 2021;49:300060520987396. [PMID: 33478296 DOI: 10.1177/0300060520987396] [Reference Citation Analysis]
2 Arora C, Kaur D, Naorem LD, Raghava GPS. Prognostic biomarkers for predicting papillary thyroid carcinoma patients at high risk using nine genes of apoptotic pathway. PLoS One 2021;16:e0259534. [PMID: 34767591 DOI: 10.1371/journal.pone.0259534] [Reference Citation Analysis]
3 You H, Wang D, Wei L, Chen J, Li H, Liu Y, Hou Y. Deferoxamine Inhibits Acute Lymphoblastic Leukemia Progression through Repression of ROS/HIF-1α, Wnt/β-Catenin, and p38MAPK/ERK Pathways. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/8281267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pita-grisanti V, Chasser K, Sobol T, Cruz-monserrate Z. Understanding the Potential and Risk of Bacterial Siderophores in Cancer. Front Oncol 2022;12:867271. [DOI: 10.3389/fonc.2022.867271] [Reference Citation Analysis]
5 Abdelaal G, Veuger S. Reversing oncogenic transformation with iron chelation. Oncotarget 2021;12:106-24. [PMID: 33520115 DOI: 10.18632/oncotarget.27866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang L, Kong L, Yang Y. miR-18a Inhibitor Suppresses Leukemia Cell Proliferation by Upregulation of PTEN Expression. Med Sci Monit 2020;26:e921288. [PMID: 32146479 DOI: 10.12659/MSM.921288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Natarajan A, Thangarajan R, Kesavan S. Repurposing Drugs by In Silico Methods to Target BCR Kinase Domain in Chronic Myeloid Leukemia. Asian Pac J Cancer Prev 2019;20:3399-406. [PMID: 31759365 DOI: 10.31557/APJCP.2019.20.11.3399] [Reference Citation Analysis]
8 Pawlaczyk M, Schroeder G. Deferoxamine-Modified Hybrid Materials for Direct Chelation of Fe(III) Ions from Aqueous Solutions and Indication of the Competitiveness of In Vitro Complexing toward a Biological System. ACS Omega 2021;6:15168-81. [PMID: 34151096 DOI: 10.1021/acsomega.1c01411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]